HUMANTIVIRUSES

Human Antibody Responses to Viruses

Coordinatore	INSTITUT PASTEUR    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	France [FR]
Totale costo	1˙499˙998 €
EC contributo	1˙499˙998 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2013-StG
Funding Scheme	ERC-SG
Anno di inizio	2014
Periodo (anno-mese-giorno)	2014-01-01   -   2018-12-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	INSTITUT PASTEUR  Organization address address: RUE DU DOCTEUR ROUX 25-28 city: PARIS CEDEX 15 postcode: 75724 contact info Titolo: Dr. Nome: Hugo Denis Misaël Bernard Cognome: Mouquet Email: send email Telefono: +33 1 40 61 36 12 Fax: +33 1 44 38 91 65	FR (PARIS CEDEX 15)	hostInstitution	1˙499˙998.00
2	INSTITUT PASTEUR  Organization address address: RUE DU DOCTEUR ROUX 25-28 city: PARIS CEDEX 15 postcode: 75724 contact info Titolo: Dr. Nome: Marie-Laure Cognome: Rosso Email: send email Telefono: +33 1 44 38 95 26 Fax: +33 1 40 61 39 40	FR (PARIS CEDEX 15)	hostInstitution	1˙499˙998.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'In addition to polyreactive “natural antibodies” that act as the first line of defense against invading pathogens, “humoral memory” is composed of high affinity antibodies that mediate long-lived immunity against infectious agents, e.g., providing protection against re-infection. The molecular dissection of anti-pathogen B-cell responses using modern technologies to generate specific monoclonal antibodies allowed breakthrough discoveries on antiviral responses to Influenza and HIV. The goal of this proposal is to study memory B-cell antibody responses to human pathogens, especially viruses, by generating and characterizing envelope specific antibodies from infected patients. I propose three aims to address what I believe to be some of the most exciting questions in the field of antiviral B-cell immunity. I propose to study: (i) the development and dynamics of memory B-cell responses to HIV; (ii) the mucosal antibody response to HIV; (iii) the memory B-cell response to Chikungunya virus. The antibodies that will be produced may be of therapeutic interest, but more importantly, their characterization will lead to a better understanding of human antibody responses to infectious agents, and may uncover candidate immunogens for vaccine development.'